The Angiotensin Converting Enzyme pipeline drugs market research report outlays comprehensive information on the Angiotensin Converting Enzyme targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Angiotensin Converting Enzyme pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Infectious Disease, Metabolic Disorders, and Hematological Disorders which include the indications Hypertension, Congestive Heart Failure (Heart Failure), Coronavirus Disease 2019 (COVID-19), Hypercholesterolemia, and Blood Coagulation. It also reviews key players involved in Angiotensin Converting Enzyme targeted therapeutics development with respective active and dormant or discontinued products.
The Angiotensin Converting Enzyme pipeline targets constitutes close to 11 molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 1, 1, 1, 1, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Angiotensin Converting Enzyme overview
Angiotensin-converting enzyme, or ACE, is a central component of the renin–angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. It converts the hormone angiotensin I to the active vasoconstrictor angiotensin II. ACE also inactivates the vasodilator protein, bradykinin.
For a complete picture of Angiotensin Converting Enzyme’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
